The antiviral agent ribavirin is effective against several virally induced diseases, and there is evidence that it might prove useful against human immunodeficiency virus type 1 (HIV-1) infection. Thus, there is interest in studying the resistance level of HIV-1 isolates to ribavirin following drug therapy. Low-passage clinical strains of HIV-1 were isolated from 3 patients undergoing treatment with ribavirin for 5-9 months. No significant changes in drug sensitivity were seen for sequential virus samples obtained before, during, and after antiviral therapy. These observations suggest that the appearance of a resistant phenotype is not induced by treatment with ribavirin in HIV-1-infected persons.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/175.1.176 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comorbidities, drug-resistance and length of hospital stay among tuberculosis inpatients in Northeastern China: a retrospective observational study from 2013 to 2021.
BMC Infect Dis
December 2024
Infectious Disease Hospital of Heilongjiang Province, No. 1 Jian She Street, Hulan District, Harbin, Heilongjiang, 150500, China.
Background: Tuberculosis (TB) remains a significant global health issue. Drug-resistant TB and comorbidities exacerbate its burden, influencing treatment outcomes and healthcare utilization. Despite the growing prevalence of TB comorbidities, research often focuses on single comorbidities rather than comorbidity patterns.
View Article and Find Full Text PDFHighly Sensitive LC-MS/MS Method for Determination of Dexamethasone in Rat Plasma and Brain Tissue: An Application to Pharmacokinetic Study in Rats.
Biomed Chromatogr
January 2025
Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Hyderabad, India.
A highly sensitive and rapid LC-MS/MS method was developed and validated for the quantification of dexamethasone in rat plasma and brain tissue. Protein precipitation method was used for sample preparation. The separation of dexamethasone and the IS (labetalol) was achieved on an Atlantis dC column using an isocratic mobile phase (10 mM ammonium formate and acetonitrile, 25/75, v/v) delivered at 0.
View Article and Find Full Text PDFTranscriptomic data integration and analysis revealing potential mechanisms of doxorubicin resistance in chondrosarcoma cells.
Biochem Pharmacol
December 2024
Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung 41354, Taiwan; Graduate Institute of Biomedical Science, China Medical University, Taichung 40402, Taiwan; Department of Pharmacology, School of Medicine, China Medical University, Taichung 40402, Taiwan; Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan; Department of Medical Research, China Medical University Hsinchu Hospital, Hsinchu 30205, Taiwan. Electronic address:
Chondrosarcoma is a type of bone cancer that originates from cartilage cells. In clinical practice, surgical resection is the primary treatment for chondrosarcoma, but chemotherapy becomes essential for patients with metastasis or tumors in surgically inaccessible sites. However, drug resistance often leads to treatment failure.
View Article and Find Full Text PDFDesign, synthesis and biological evaluation of camptothecin analogue FL118 as a payload for antibody-drug conjugates in targeted cancer therapy.
Bioorg Med Chem Lett
December 2024
Pinotbio, Inc Suwon, Gyeonggi-do 16506, South Korea.
FL118, a camptothecin derivative with dual mechanisms of action through topoisomerase I inhibition and proteasome-mediated degradation of anti-apoptotic proteins exhibits potent anti-tumor activity while remaining resistant to drug efflux transporters. This work describes the targeted delivery of FL118 to tumors via antibody-drug conjugates (ADCs) using the pH-sensitive CL2A linker. ADCs targeting Trop2, HER2, and EGFR exhibited potent in vitro cytotoxicity, with IC values as low as 0.
View Article and Find Full Text PDFExposure therapy consortium: Outcomes of the proof-of-principle study.
J Anxiety Disord
December 2024
Institut für Psychologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
Background: This paper reports on the outcomes of a proof-of-principle study for the Exposure Therapy Consortium, a global network of researchers and clinicians who work to improve the effectiveness and uptake of exposure therapy. The study aimed to test the feasibility of the consortium's big-team science approach and test the hypothesis that adding post-exposure processing focused on enhancing threat reappraisal would enhance the efficacy of a one-session large-group interoceptive exposure therapy protocol for reducing anxiety sensitivity.
Methods: The study involved a multi-site cluster-randomized controlled trial comparing exposure with post-processing (ENHANCED), exposure without post-processing (STANDARD), and a stress management intervention (CONTROL) in students with elevated anxiety sensitivity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!